<DOC>
	<DOCNO>NCT00052780</DOCNO>
	<brief_summary>Phase I trial study safety combine O6-benzylguanine temozolomide treat child recurrent refractory brain tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . O6-benzylguanine may increase effectiveness temozolomide make tumor cell sensitive drug .</brief_summary>
	<brief_title>Temozolomide O6-Benzylguanine Treating Children With Recurrent Brain Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose temozolomide ( Temodar ) administer O6-benzylguanine ( O6-BG ) without G-CSF support pediatric patient refractory brain tumor stratify previous radiotherapy . SECONDARY OBJECTIVES : I . To characterize pharmacokinetics temozolomide O6-BG use combination . II . To characterize toxicity associate combination O6-BG temozolomide without G-CSF support . III . To document antitumor response patient treat O6-BG temozolomide . IV . To determine level MGMT enzyme mismatch repair ( MMR ) proteins tumor tissue , investigate possible correlation patient outcome . OUTLINE : This dose-escalation study temozolomide without filgrastim ( G-CSF ) . Patients stratify accord prior radiotherapy ( RT ) /myeloablative therapy ( RT focal RT v craniospinal RT myeloablative therapy ) . Patients receive O6-benzylguanine IV continuously day 1 2 oral temozolomide day 1 . Treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Cohorts 2-6 patient stratum receive escalating dos temozolomide maximum tolerate dose ( MTD ) determine . The MTD define dose 25 % patient experience DLT . Once MTD determine , additional patient treat dose level total 12 patient treated MTD . For course 1-12 , patient experience neutropenia may also receive G-CSF subcutaneously IV daily begin day 3 continue blood count recover . If neutropenia dose-limiting toxicity ( DLT ) first 2 stratum , patient stratify accord concurrent G-CSF support ( yes v ) .Cohorts 3-6 patient stratum receive escalating dos temozolomide G-CSF MTD determine . The MTD define dose precede least 2 3 2 6 patient experience DLT . Once MTD determine , 6 additional patient treat dose . Patients follow resolution adverse event occur treatment and/or within 30 day last administration study drug . Patients follow short 1 ) three month last protocol base treatment , 2 ) date therapy initiate .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Choroid Plexus Neoplasms</mesh_term>
	<mesh_term>Optic Nerve Glioma</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<criteria>Recurrent refractory pediatric brain tumor ; histopathologic diagnosis either initial presentation time recurrence require brain stem gliomas Karnofsky Lansky ≥ 60 % Life expectancy &gt; 8 week Patients neurological deficit deficit stable minimum 1 week prior study entry Chemotherapy : No 2 previous chemotherapy/biologic therapy regimens ; evidence recovery prior chemotherapy/biologic therapy ; myelosuppressive chemotherapy within 3 week ( 6 week nitrosourea agent ) study entry ; patient receive temozolomide eligible receive drug past 3 month experience nonhematopoietic Grade 3/4 toxicity prior temozolomide therapy XRT : ≥ 3 month prior study entry craniospinal irradiation ( ≥ 18 Gy ) ; ≥ 4 week local radiation primary tumor ; ≥ 2 week prior study entry focal irradiation symptomatic metastatic site Bone Marrow Transplant : ≥ 6 month prior study entry Anticonvulsants : Patients eligible study even receive anticonvulsant Growth factor : Off colony form growth factor ( ) &gt; 2 week prior study entry ( GCSF , GMCSF , Erythropoietin ) Dexamethasone : Patients receive dexamethasone must stable dose least 1 week prior study entry ANC &gt; 1,000/μl Platelets &gt; 100,000/μl Hemoglobin &gt; 8g/dl Patients may bone marrow involvement disease ; platelet Hgb count must transfusion independent Creatinine ≤ 1.5 time institutional normal age Or GFR &gt; 70 ml/min/1.73m^2 Bilirubin ≤ upper limit normal age SGPT ( ALT ) &lt; SGOT ( AST ) &lt; 2.5X institutional normal No overt renal , hepatic , cardiac pulmonary disease Female patient childbearing potential must negative serum urine pregnancy test ; patient must pregnant breastfeeding ; know teratogenic effect know O6BG far , little data address specifically ; , prudent approach exclude pregnant breastfeeding patient data available Patients childbearing childfathering potential must willing use medically acceptable form birth control , include abstinence , treat study Signed informed consent accord institutional guideline must obtain patient must begin therapy within seven ( 7 ) day registration Patients must receive anticancer experimental drug therapy Patients history hypersensitivity dacarbazine , temozolomide polyethylene glycol exclude</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>